Cargando…

Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial

ABSTRACT: This study compares the effectiveness and safety of oxytocin infusion against oral misoprostol for inducing labour in pregnant women with term prelabor membrane rupture. We randomized 173 pregnant women presenting with term prelabor rupture of membranes (PROM) at Ain Shams University Mater...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Rania Hassan Mostafa, Sweed, Mohamed Samir Eid, El-Bishry, Gasser Adly, Hassan, Raghda Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692250/
https://www.ncbi.nlm.nih.gov/pubmed/37442883
http://dx.doi.org/10.1007/s43032-023-01290-0
_version_ 1785152902813188096
author Ahmed, Rania Hassan Mostafa
Sweed, Mohamed Samir Eid
El-Bishry, Gasser Adly
Hassan, Raghda Khaled
author_facet Ahmed, Rania Hassan Mostafa
Sweed, Mohamed Samir Eid
El-Bishry, Gasser Adly
Hassan, Raghda Khaled
author_sort Ahmed, Rania Hassan Mostafa
collection PubMed
description ABSTRACT: This study compares the effectiveness and safety of oxytocin infusion against oral misoprostol for inducing labour in pregnant women with term prelabor membrane rupture. We randomized 173 pregnant women presenting with term prelabor rupture of membranes (PROM) at Ain Shams University Maternity Hospital into Group A (underwent induction of labor (IOL) by 25μg misoprostol oral tablet every 4 h, for maximum 5 doses) and an identical Group B: (underwent IOL by oxytocin infusion according to the hospital protocol). Our primary outcome was rate of vaginal delivery within 24 h, while the secondary outcomes included the time till active phase, induction to delivery interval, maternal pyrexia, nausea and vomiting, fetal distress, Apgar score, birth weight, and neonatal intensive care unit admission. Both groups showed high rates of vaginal delivery (82.4% & 87.1% for misoprostol group and oxytocin group respectively) with no significant difference between the two groups (p=0.394). However, patients induced by misoprostol took significantly less time to reach active phase with a shorter induction to delivery interval as compared to patients induced with oxytocin. This difference was clear in multiparous women, but not observed in primiparous women when subgroup analysis was done. No significant difference was found as regards other outcomes. Our study showed that both oral misoprostol and oxytocin are effective and safe for IOL in patients with PROM, with shorter induction-delivery interval in patients induced by oral misoprostol, an effect that is clear in multiparous but not primiparous women. TRIAL REGISTRATION: NCT05215873, on 31/01/2022, “retrospectively registered”. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43032-023-01290-0.
format Online
Article
Text
id pubmed-10692250
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106922502023-12-03 Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial Ahmed, Rania Hassan Mostafa Sweed, Mohamed Samir Eid El-Bishry, Gasser Adly Hassan, Raghda Khaled Reprod Sci Maternal Fetal Medicine/Biology: Original Article ABSTRACT: This study compares the effectiveness and safety of oxytocin infusion against oral misoprostol for inducing labour in pregnant women with term prelabor membrane rupture. We randomized 173 pregnant women presenting with term prelabor rupture of membranes (PROM) at Ain Shams University Maternity Hospital into Group A (underwent induction of labor (IOL) by 25μg misoprostol oral tablet every 4 h, for maximum 5 doses) and an identical Group B: (underwent IOL by oxytocin infusion according to the hospital protocol). Our primary outcome was rate of vaginal delivery within 24 h, while the secondary outcomes included the time till active phase, induction to delivery interval, maternal pyrexia, nausea and vomiting, fetal distress, Apgar score, birth weight, and neonatal intensive care unit admission. Both groups showed high rates of vaginal delivery (82.4% & 87.1% for misoprostol group and oxytocin group respectively) with no significant difference between the two groups (p=0.394). However, patients induced by misoprostol took significantly less time to reach active phase with a shorter induction to delivery interval as compared to patients induced with oxytocin. This difference was clear in multiparous women, but not observed in primiparous women when subgroup analysis was done. No significant difference was found as regards other outcomes. Our study showed that both oral misoprostol and oxytocin are effective and safe for IOL in patients with PROM, with shorter induction-delivery interval in patients induced by oral misoprostol, an effect that is clear in multiparous but not primiparous women. TRIAL REGISTRATION: NCT05215873, on 31/01/2022, “retrospectively registered”. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43032-023-01290-0. Springer International Publishing 2023-07-13 /pmc/articles/PMC10692250/ /pubmed/37442883 http://dx.doi.org/10.1007/s43032-023-01290-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Maternal Fetal Medicine/Biology: Original Article
Ahmed, Rania Hassan Mostafa
Sweed, Mohamed Samir Eid
El-Bishry, Gasser Adly
Hassan, Raghda Khaled
Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial
title Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial
title_full Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial
title_fullStr Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial
title_full_unstemmed Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial
title_short Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women with Term Prelabor Rupture of Membranes: a Randomized Clinical Trial
title_sort oxytocin versus oral misoprostol for induction of labor in pregnant women with term prelabor rupture of membranes: a randomized clinical trial
topic Maternal Fetal Medicine/Biology: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692250/
https://www.ncbi.nlm.nih.gov/pubmed/37442883
http://dx.doi.org/10.1007/s43032-023-01290-0
work_keys_str_mv AT ahmedraniahassanmostafa oxytocinversusoralmisoprostolforinductionoflaborinpregnantwomenwithtermprelaborruptureofmembranesarandomizedclinicaltrial
AT sweedmohamedsamireid oxytocinversusoralmisoprostolforinductionoflaborinpregnantwomenwithtermprelaborruptureofmembranesarandomizedclinicaltrial
AT elbishrygasseradly oxytocinversusoralmisoprostolforinductionoflaborinpregnantwomenwithtermprelaborruptureofmembranesarandomizedclinicaltrial
AT hassanraghdakhaled oxytocinversusoralmisoprostolforinductionoflaborinpregnantwomenwithtermprelaborruptureofmembranesarandomizedclinicaltrial